Insulinomas or beta cell hyperplasia causing hyperinsulinemic hypoglycemia, as well as congenital hyperinsulinism (CHI) requiring surgical treatment.
Conditions
Interventions
Hyperinsulinemia group:injection of 68Ga-exendin-4
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
No minimum to 99 Years
Inclusion criteria
Inclusion criteria: 1. The patient or their legal representative signs an informed consent form with a signature and date. 2. Commitment to adhere to the study procedures and cooperate with the entire research process. 3. No restrictions on age or gender. 4. Patients clinically diagnosed with hyperinsulinemia who require clarification of the etiology, or patients with a history of insulinoma who still experience recurrent hypoglycemic episodes.
Exclusion criteria
Exclusion criteria: 1. Patients who are pregnant or breastfeeding; 2. Patients or their legal representatives are unable or unwilling to sign the informed consent form; 3. Acute systemic diseases and electrolyte imbalances; 4. Patients known to be allergic to GLP-1R receptor imaging agents or synthetic excipients; 5. Patients who are unable to complete the PET/MR or PET/CT examination (including those unable to lie flat, with claustrophobia, radiationophobia, etc.); 6. Patients who, in the opinion of the researcher, have poor compliance or other factors that are not suitable for participating in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUVmax, SUVmean, descending aorta SUVmax, right hepatic lobe mean SUVmax, Lesion SUVmax to liver SUVmean ratio (LLR), and lesion SUVmax to pancreas SUVmean ratio (LPR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Medical history related to hypoglycemia; | — |
Countries
China
Contacts
Public ContactXiaoli Lan
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed